The recent hantavirus outbreak aboard the MV Hondius cruise ship has brought increased attention to an infection for which there are no widely available or FDA-approved therapeutics or vaccines, with ...

A few months after winning its first regulatory clearance in China, Beone Medicines Inc.’s next-generation BCL2 inhibitor, ...

Metis Techbio Co. Ltd. is seeking a potential HK$2.11 billion (US$270 million) raise through a stock sale May 13, marking the ...

Med-tech financing activity in the first four months of 2026 reached $10.05 billion, similar to 2025’s $10.31 billion and ...

Rigel Pharmaceuticals Inc. CEO Raul Rodriguez said breast cancer therapy Veppanu (vepdegestrant) could become his firm’s “largest product with the current label,” and other opportunities with the drug ...

A designed chimeric virus induced broadly neutralizing antibodies against the macaque equivalent of HIV. The strategy works ...

In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early development programs in the fields of ...

Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out ...

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Capsida, Cellular Intelligence, Novo Nordisk, Nxera.

The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a ...

Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical ...

Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day.